Second Death in Duchenne Gene Therapy Sparks Safety Concerns and Trial Halt
TL;DR Summary
Following the death of a second patient treated with Elevidys for Duchenne muscular dystrophy, families and advocates are calling for greater transparency, improved safety data collection, and stronger regulatory oversight to ensure patient safety and informed decision-making in the use of this high-cost gene therapy.
- Following second patient death, Duchenne muscular dystrophy families deserve answers about Elevidys STAT
- Second patient death reported with gene therapy for muscular dystrophy AP News
- Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients Fierce Pharma
- Biotech pauses trial after second patient death linked to gene therapy The Washington Post
- Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics BioSpace
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
7 min
vs 8 min read
Condensed
97%
1,415 → 45 words
Want the full story? Read the original article
Read on STAT